Literature DB >> 26519857

Drug delivery of the future: Chasing the invisible gorilla.

Kinam Park1.   

Abstract

For more than 60years drug delivery systems have produced numerous controlled release formulations helping patients improve compliance and maximize the drug efficacy. Development of new controlled drug delivery systems was very productive during the period 1950-1980. The productivity, as measured by the number of clinically used formulations, dropped significantly during 1980-2010. This reduced productivity needs to be understood so that the future development of drug delivery systems can be accelerated and prolific again. This requires critical evaluation of the current drug delivery field, so that the factors inhibiting rapid progress can be identified and resolved. The current drug delivery field is faced with an invisible gorilla syndrome, i.e., seeing a gorilla when it is not present and missing a gorilla when it actually exists. Overcoming this syndrome requires a new way of thinking, questioning the status quo. Advances in drug delivery technologies occur by an evolutionary process, and thus, the more trials and errors lead to faster advances. The drug delivery area needs to nurture the environment where vastly different ideas can be tested, and all data, positive or negative, need to be exchanged freely as they have equal importance.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug delivery; Future; Invisible gorilla; Nanoparticle

Mesh:

Substances:

Year:  2015        PMID: 26519857      PMCID: PMC4848181          DOI: 10.1016/j.jconrel.2015.10.048

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  18 in total

Review 1.  A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole.

Authors:  Lars Olbe; Enar Carlsson; Per Lindberg
Journal:  Nat Rev Drug Discov       Date:  2003-02       Impact factor: 84.694

2.  Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study.

Authors:  Aaron C Eifler; C Shad Thaxton
Journal:  Methods Mol Biol       Date:  2011

3.  Translation from mouse to human: time to think in new boxes.

Authors:  Kinam Park
Journal:  J Control Release       Date:  2014-09-10       Impact factor: 9.776

4.  Targeted drug delivery to tumors: myths, reality and possibility.

Authors:  You Han Bae; Kinam Park
Journal:  J Control Release       Date:  2011-06-06       Impact factor: 9.776

5.  Controlled drug delivery systems: past forward and future back.

Authors:  Kinam Park
Journal:  J Control Release       Date:  2014-04-30       Impact factor: 9.776

Review 6.  Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.

Authors:  Darren Lars Stirland; Joseph W Nichols; Seiji Miura; You Han Bae
Journal:  J Control Release       Date:  2013-10-02       Impact factor: 9.776

7.  Look back in anger - what clinical studies tell us about preclinical work.

Authors:  Thomas Hartung
Journal:  ALTEX       Date:  2013       Impact factor: 6.043

8.  In vitro studies of poly(methyl methacrylate) adjuvants.

Authors:  J Kreuter; P P Speiser
Journal:  J Pharm Sci       Date:  1976-11       Impact factor: 3.534

9.  Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency.

Authors:  P Jani; G W Halbert; J Langridge; A T Florence
Journal:  J Pharm Pharmacol       Date:  1990-12       Impact factor: 3.765

10.  Why most published research findings are false.

Authors:  John P A Ioannidis
Journal:  PLoS Med       Date:  2005-08-30       Impact factor: 11.613

View more
  14 in total

Review 1.  Watching the gorilla and questioning delivery dogma.

Authors:  Thomas J Anchordoquy; Dmitri Simberg
Journal:  J Control Release       Date:  2017-07-14       Impact factor: 9.776

2.  Albumin-coated nanocrystals for carrier-free delivery of paclitaxel.

Authors:  Joonyoung Park; Bo Sun; Yoon Yeo
Journal:  J Control Release       Date:  2016-12-31       Impact factor: 9.776

Review 3.  Nanotechnology to improve the Alzheimer's disease therapy with natural compounds.

Authors:  Maria João Ramalho; Stephanie Andrade; Joana Angélica Loureiro; Maria do Carmo Pereira
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

Review 4.  Multiorgan Microphysiological Systems for Drug Development: Strategies, Advances, and Challenges.

Authors:  Ying I Wang; Carlos Carmona; James J Hickman; Michael L Shuler
Journal:  Adv Healthc Mater       Date:  2017-12-04       Impact factor: 9.933

5.  Drug Delivery Research: The Invention Cycle.

Authors:  Kinam Park
Journal:  Mol Pharm       Date:  2016-03-17       Impact factor: 4.939

6.  Nanoparticle uptake by circulating leukocytes: A major barrier to tumor delivery.

Authors:  Jamie L Betker; Dallas Jones; Christine R Childs; Karen M Helm; Kristina Terrell; Maria A Nagel; Thomas J Anchordoquy
Journal:  J Control Release       Date:  2018-07-17       Impact factor: 9.776

7.  Modified gaphene oxide (GO) particles in peptide hydrogels: a hybrid system enabling scheduled delivery of synergistic combinations of chemotherapeutics.

Authors:  John D Schneible; Kaihang Shi; Ashlyn T Young; Srivatsan Ramesh; Nanfei He; Clay E Dowdey; Jean Marie Dubnansky; Radina L Lilova; Wei Gao; Erik Santiso; Michael Daniele; Stefano Menegatti
Journal:  J Mater Chem B       Date:  2020-05-06       Impact factor: 6.331

8.  Fabrication of novel vesicles of triptolide for antirheumatoid activity with reduced toxicity in vitro and in vivo.

Authors:  Li Zhang; Tengteng Wang; Qiang Li; Jing Huang; Hao Xu; Jinlong Li; Yongjun Wang; Qianqian Liang
Journal:  Int J Nanomedicine       Date:  2016-06-08

Review 9.  Current Challenges toward In Vitro Cellular Validation of Inorganic Nanoparticles.

Authors:  Malou Henriksen-Lacey; Susana Carregal-Romero; Luis M Liz-Marzán
Journal:  Bioconjug Chem       Date:  2016-10-19       Impact factor: 4.774

10.  Editorial for biomimetic nanoparticles for drug delivery.

Authors:  Jianxin Wang
Journal:  Acta Pharm Sin B       Date:  2018-02-03       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.